Ben Fidler, deputy editor of biotechnology at Xconomy, is departing the website.
He has been at Xconomy since April 2013.
“Thanks to Xconomy for the opportunity, my colleagues for being true family, and to all you readers for the support and insightful feedback over the years!” he wrote on Twitter.
Fidler joined Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming.
He was The Deal’s senior health care writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Fidler wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act.
Before switching to the health care beat, Fidler was The Deal’s senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others.
New York Times executive editor Joe Kahn sent out the following on Thursday: Without a doubt, the…
Helen Reis has joined SoFi as deputy newsletter editor for its new On the Money…
The Financial Times has announced the appointment of Jay Rayner as restaurant critic, Tim Hayward…
Dow Jones Newswires has launched its first artificial intelligence-enabled language service. The Dow Jones Korean…
Jon Delano, money and politics editor for KDKA-TV since 2001, will retire on Dec. 1.…
Bloomberg News journalist Megan Howard is joining its financial regulation team. She has been team leader for…